TOI
Oncology Institute Inc (The)

756
Mkt Cap
$307.93M
Volume
2.33M
52W High
$4.88
52W Low
$0.145
PE Ratio
-4.73
TOI Fundamentals
Price
$3.04
Prev Close
$3.13
Open
$3.20
50D MA
$3.78
Beta
1.28
Avg. Volume
2M
EPS (Annual)
-$0.7063
P/B
-24.17
Rev/Employee
$476,863.03
Loading...
Loading...
News
all
press releases
Oncology Institute (NASDAQ:TOI) Director Mark Pacala Sells 50,000 Shares
The Oncology Institute, Inc. (NASDAQ:TOI - Get Free Report) Director Mark Pacala sold 50,000 shares of the company's stock in a transaction on Tuesday, November 18th. The shares were sold at an...
MarketBeat·4d ago
News Placeholder
More News
News Placeholder
Stock Traders Purchase High Volume of Oncology Institute Call Options (NASDAQ:TOI)
The Oncology Institute, Inc. (NASDAQ:TOI - Get Free Report) was the target of unusually large options trading on Wednesday. Traders purchased 7,930 call options on the stock. This represents an...
MarketBeat·4d ago
News Placeholder
Oncology Institute (NASDAQ:TOI) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS
Oncology Institute (NASDAQ:TOI - Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate...
MarketBeat·9d ago
News Placeholder
Tiff Advisory Services LLC Raises Stock Position in The Oncology Institute, Inc. $TOI
Tiff Advisory Services LLC lifted its holdings in shares of The Oncology Institute, Inc. (NASDAQ:TOI - Free Report) by 22.0% in the second quarter, according to the company in its most recent filing...
MarketBeat·10d ago
News Placeholder
The Oncology Institute, Inc. (TOI) Reports Q3 Loss, Beats Revenue Estimates
The Oncology Institute (TOI) delivered earnings and revenue surprises of -16.67% and +11.71%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·11d ago
News Placeholder
Biorestorative Therapies, Inc. (BRTX) Reports Q3 Loss, Lags Revenue Estimates
Biorestorative Therapies (BRTX) delivered earnings and revenue surprises of 0.00% and -97.00%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·12d ago
News Placeholder
Establishment Labs Holdings Inc. (ESTA) Reports Q3 Loss, Beats Revenue Estimates
Establishment Labs (ESTA) delivered earnings and revenue surprises of +29.63% and +3.45%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·20d ago
News Placeholder
CryoPort, Inc. (CYRX) Reports Q3 Loss, Tops Revenue Estimates
CryoPort (CYRX) delivered earnings and revenue surprises of +21.74% and +8.32%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·20d ago
News Placeholder
Avantor, Inc. (AVTR) Q3 Earnings and Revenues Miss Estimates
Avantor (AVTR) delivered earnings and revenue surprises of -4.35% and -1.56%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·27d ago
News Placeholder
The Oncology Institute (TOI) Loses 20% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The Oncology Institute (TOI) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Zacks·2mo ago

Latest TOI News

View

Advertisement|Remove ads.

Advertisement|Remove ads.